title: Treatment of herpes simplex gingivostomatitis with aciclovir in children: a randomised double blind placebo controlled study.
abstract: OBJECTIVE
  To examine the efficacy of aciclovir suspension for treating herpetic gingivostomatitis in young children.
  
  
  METHODS
  Randomised double blind placebo controlled study.
  
  
  METHODS
  Day care unit of a tertiary paediatric hospital.
  
  
  METHODS
  72 children aged 1-6 years with clinical manifestations of gingivostomatitis lasting less than 72 hours; 61 children with cultures positive for herpes simplex virus finished the study.
  
  
  METHODS
  Duration of oral lesions, fever, eating and drinking difficulties, and viral shedding.
  
  
  METHODS
  Aciclovir suspension 15 mg/kg five times a day for seven days, or placebo.
  
  
  RESULTS
  Children receiving aciclovir had oral lesions for a shorter period than children receiving placebo (median 4 v 10 days (difference 6 days, 95% confidence interval 4.0 to 8.0)) and earlier disappearance of the following signs and symptoms: fever (1 v 3 days (2 days, 0.8 to 3.2)); extraoral lesions (lesions around the mouth but outside the oral cavity) (0 v 5.5 days (5.5 days, 1.3 to 4.7)); eating difficulties (4 v 7 days (3 days, 1.31 to 4.69)); and drinking difficulties (3 v 6 days (3 days, 1.1 to 4.9)). Viral shedding was significantly shorter in the group treated with aciclovir (1 v 5 days (4 days, 2.9 to 5.1)).
  
  
  CONCLUSIONS
  Oral aciclovir treatment for herpetic gingivostomatitis, started within the first three days of onset, shortens the duration of all clinical manifestations and the infectivity of affected children. Further studies are needed to evaluate the ideal dose and length of treatment.
authors.affiliation: Paediatric Ambulatory Care Unit, Golda Medical Centre, Hasharon Hospital, Petah Tiqva, Israel. hshmuely@post.tau.ac.il
authors.forename: J
authors.initials: J
authors.lastname: Amir
authors.forename: L
authors.initials: L
authors.lastname: Harel
authors.forename: Z
authors.initials: Z
authors.lastname: Smetana
authors.forename: I
authors.initials: I
authors.lastname: Varsano
mesh_terms: D000212:Acyclovir / Q000009:adverse effects / Q000627:therapeutic use*; D000284:Administration, Oral; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004311:Double-Blind Method; D001068:Feeding and Eating Disorders / Q000821:virology; D005334:Fever / Q000821:virology; D018259:Herpesvirus 1, Human / Q000302:isolation & purification; D006760:Hospitalization; D006801:Humans; D007223:Infant; D010349:Patient Compliance; D012008:Recurrence; D013283:Stomatitis, Herpetic / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000212:Acyclovir